SARS News and Research

RSS

ACE2 receptor expression by SARS-CoV-2 across different animal species

A new report published on the preprint server bioRxiv in April 2020 reports that several species of animals can be infected with relative ease by the SARS-CoV-2 virus that is the causative agent of the currently raging COVID-19 pandemic. This casts much light on the possible natural hosts and routes of transmission of this virus.

20 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

ACE2-TMPRSS2 profiling indicates tissue vulnerability to SARS-CoV-2 infection

A new study published in April 2020 on the preprint server bioRxiv reports that the different levels of susceptibility of various organs to viral attack by the SARS-CoV-2 virus causing the huge pandemic of COVID-19 sweeping around the world can be predicted from the level of expression of two molecules, the ACE2 receptor, and the TMPRSS2 protein.

20 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.

20 Apr 2020

New biosensor rapidly detects SARS-CoV-2 from nasopharyngeal swabs

According to many experts, early diagnosis and management are critical for slowing the spread of SARS-CoV-2, the new coronavirus that causes COVID-19.

20 Apr 2020

Antibody detection for COVID-19 - promise and risks

Recently, several research groups emphasized how the pervasive screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may prove pivotal in determining infection seroprevalence in a given population defining previous exposure, screening health care workers, but also identifying highly reactive individuals that may act as donors for the therapeutic use of their convalescent serum.

20 Apr 2020

CRISPR technology mobilized for rapid COVID-19 diagnosis

A group of authors from the United States published a study in the scientific journal Nature Biotechnology in which they have described a CRISPR-Cas-based approach for rapid and accurate diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection – without the need for complex laboratory infrastructure.

20 Apr 2020

Researchers to develop predictive COVID-19 Intervention Modelling for East Africa

A £1m grant from the Wellcome Trust has enabled researchers from the School of Life Sciences at the University of Warwick, to work with East African countries in their emergency preparations for COVID-19 as the pandemic spreads across Africa.

20 Apr 2020

A novel method for predicting promising antiviral drug or vaccine targets

A novel method to predict the most promising targets for antiviral drugs or vaccines is based on the conformational changes viral glycoproteins go through during the process of recognition and binding to the host cell.

20 Apr 2020

EMBL-EBI and partners launch new COVID-19 Data Portal

EMBL's European Bioinformatics Institute and partners today launched the COVID-19 Data Portal, which enables the sharing and analysis of data related to the new coronavirus, SARS-CoV-2.

20 Apr 2020

Penn Medicine launches convalescent plasma therapy trial for COVID-19 patients

Convalescent plasma therapy for COVID-19 patients -- an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection -- is the focus of a new two-part research initiative at Penn Medicine.

20 Apr 2020

Remdesivir prevents COVID-19 progression to severe pneumonia, animal study shows

A team of scientists at the National Institute of Allergy and Infectious Diseases, which is part of the U.S. National Institutes of Health, has tested the efficacy of remdesivir, a nucleotide analog prodrug with a broad antiviral activity, as a COVID-19 treatment.

20 Apr 2020

Smoking doubles risk of severe COVID-19 disease

The fatality rate among infected people increases among the elderly and those with underlying medical conditions. Now, a new study published as a pre-print on medXriv, links smoking to the progression of COVID-19 disease, suggesting that the odds of disease progression is more than double in smokers.

20 Apr 2020

Poorer regions in the Philippines have more COVID-19 cases

The coronavirus disease (COVID-19) has dramatically affected European countries and the United States, reporting the highest number of confirmed cases. In Asia, though the number of infections gradually increases, some countries have reported high death rates, including Indonesia and the Philippines.

20 Apr 2020

Remote monitoring of COVID-19 patients using AI device

Massachusetts' Institute of Technology (MIT) at its Computer Science and Artificial Intelligence Laboratory (CSAIL) has developed a device that can monitor patients with the highly infective COVID-19 remotely and thus prevent the spread of the infection to healthcare workers.

19 Apr 2020

Novel coronavirus mutation could spell trouble for vaccine development

New research shows that the novel coronavirus is undergoing mutations that could make it challenging to develop a vaccine against. There are a few vaccine candidates that are in the making to prevent COVID-19. With a potential for mutation, the vaccines that are being developed now may not work against the emergent mutated strains worry Taiwanese and Australian researchers. The study is titled, “Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of 2 RBD mutant with lower ACE2 binding affinity.”

19 Apr 2020

Scientists unveil novel coronavirus variants in India

The global coronavirus disease COVID-19 pandemic is ravaging the world, affecting 185 countries and territories and infecting 2.4 million people. Now, a team of scientists aims to shed light on the variants of the novel coronavirus strains in India, showing how changes correspond to its transmission and how it causes disease.

19 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Scientists estimate fatality ratio across full spectrum of COVID-19 disease

A team of researchers from Imperial College London has conducted a study aimed at calculating a reasonably accurate case fatality ratio and infection fatality ratio, which is based on Chinese data as well as international reports. The research is published on the pre-print server MedRxiv.

19 Apr 2020